Skip to main content

CORRECTION article

Front. Med., 29 March 2022
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.888928

Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol

This article is a correction to:

  1. Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol

    1. Read original article
\nArvind ChopraArvind Chopra1Preeti Chavan-GautamPreeti Chavan-Gautam2Girish TilluGirish Tillu2Manjit SalujaManjit Saluja1Swapnil BorseSwapnil Borse2Sanjeev SarmukaddamSanjeev Sarmukaddam1Susmita ChaudhuriSusmita Chaudhuri3BCS RaoBCS Rao4Babita YadavBabita Yadav4Narayanam SrikanthNarayanam Srikanth4Bhushan Patwardhan Bhushan Patwardhan2*
  • 1Center for Rheumatic Diseases, Pune, India
  • 2Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India
  • 3Translational Health Science and Technology Institute (THSTI), Faridabad, India
  • 4Central Council for Research in Ayurvedic Science, New Delhi, India

A Corrigendum on
Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol

by Chopra, A., Chavan-Gautam, P., Tillu, G., Saluja, M., Borse, S., Sarmukaddam, S., Chaudhuri, S., Rao, B. C. S., Yadav, B., Srikanth, N., and Patwardhan, B. (2022). Front. Med. 9:761655. doi: 10.3389/fmed.2022.761655

In the original article, there was an error in the sentence “One tablet of Ashwagandha or placebo will be administered twice daily (on empty stomach in the morning and after dinner) with water.”

The correction has been made to the Eligibility section, “Trial Intervention” sub section and the corrected sentence appears below:

“One tablet of Ashwagandha or placebo will be administered daily (on empty stomach in the morning) with water.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: COVID-19, immunogenicity, Withania somnifera, vaccine, Ayurveda, Ashwagandha, immunoadjuvant

Citation: Chopra A, Chavan-Gautam P, Tillu G, Saluja M, Borse S, Sarmukaddam S, Chaudhuri S, Rao BCS, Yadav B, Srikanth N and Patwardhan B (2022) Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol. Front. Med. 9:888928. doi: 10.3389/fmed.2022.888928

Received: 03 March 2022; Accepted: 09 March 2022;
Published: 29 March 2022.

Edited and reviewed by: Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France

Copyright © 2022 Chopra, Chavan-Gautam, Tillu, Saluja, Borse, Sarmukaddam, Chaudhuri, Rao, Yadav, Srikanth and Patwardhan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Bhushan Patwardhan, YnBhdHdhcmRoYW4mI3gwMDA0MDtnbWFpbC5jb20=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.